The company has completed the patient enrollment in the P-III study (MANIFEST-2) evaluating pelabresib (BET inhibitor) + ruxolitinib vs ruxolitinib alone in a ratio (1:1) in 400+ patients with myelofibrosis who have not prior treated with a JAK inhibitor. The results are expected at the end of 2023
The 1EPs of the trial is the proportion of patients achieved a ≥35% reduction in spleen volume @24wk. & the 2EPs is the proportion of patients who achieved a ≥50% improvement in total symptom score @24wk.
The trial was based on the P-II trial (MANIFEST) results. Additionally, patients enrollment in the P-III study (frontMIND) for tafasitamab is also complete in 1L diffuse large B-cell lymphoma & the results are expected in H2’25
Ref: MorphoSys | Image: MorphoSys
Related News:- MorphoSys Reports (L-MIND) Study Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
